OBI Pharma and TegMine Therapeutics Sign Commercial License Agreement for Glycoprotein-Targeting ADC
2025.Dec.18
News
OBI Investors’ Meeting Highlights Value Transformation Driven by ADC Innovation
2025.Dec.05
News
OBI-902 Receives Consecutive FDA Orphan Drug Designation
Indication Expanded to Gastric Cancer Including Gastroesophageal Junction Adenocarcinoma
2025.Nov.16
News
OBI-902 has been granted by US FDA for Orphan Drug Designation for the treatment of Cholangiocarcinoma.
2025.Sep.26
News
OBI Invited to Present ADC Technology Platform and Chaired Sessions at Biologics World Korea 2025
2025.Sep.03
News
OBI Pharma and AP Biosciences Sign Technology Collaboration Agreement to Develop Next-Generation ADC
2025.Aug.31
News
OBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in Advanced Solid Tumors
2025.Jul.22
News
OBI Pharma Showcases Innovative Pipeline, Platforms, and Technologies at BIO Asia–Taiwan 2025
GlycOBI® and HYPrOBI™ Drive the Advancement of Bispecific, Dual-Payload ADCs
2025.Jun.10
News
OBI Pharma Showcases Next-Generation ADC Development at 2025 World ADC Asia Summit
2025.Jun.06
News
OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies
2025.Mar.12
News
OBI Pharma Receives ‘Most Promising ADC Clinical Candidate in Taiwan’ Award
Dr. Heidi Wang Accepts Award on Behalf of OBI Pharma at ADC Asia Congress 2025 and Gives a Presentation
Events
Investor
2025 Investor Meeting
2025.Dec.18 at 02:30 PM
Taipei Bioinnovation Park 1F Conference Room
Event Time2025.Dec.18
Event LocationTaipei Bioinnovation Park 1F Conference Room
